DLB
MCID: DMN031
MIFTS: 66

Dementia, Lewy Body (DLB)

Categories: Genetic diseases, Mental diseases, Rare diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 57 25 74 13
Lewy Body Dementia 57 12 53 25 54 74 37 29 6 43 15 40 17
Lewy Body Disease 12 53 25 55 44 72
Diffuse Lewy Body Disease 57 12 53 25 74
Dementia with Lewy Bodies 12 75 25 54 15
Dlb 57 53 25 74
Autosomal Dominant Diffuse Lewy Body Disease 53 72
Diffuse Lewy Body Disease with Gaze Palsy 74
Lewy Body Variant of Alzheimer Disease 74
Dementia, Lewy Body, Susceptibility to 6
Lewy Body Dementia, Susceptibility to 57
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 25
Lewy Body Type Senile Dementia 74
Dysphasic Dementia Hereditary 74
Cortical Lewy Body Disease 74
Lewy Bodies 29
Lbd 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


HPO:

32
dementia, lewy body:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12217
OMIM 57 127750
KEGG 37 H00066
ICD9CM 35 331.82
MeSH 44 D020961
NCIt 50 C84826
SNOMED-CT 68 80098002
ICD10 33 G31.83
UMLS 72 C0752347 C2931906

Summaries for Dementia, Lewy Body

MedlinePlus : 43 What is Lewy body dementia (LBD)? Lewy body dementia (LBD) is one of the most common types of dementia in older adults. Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention What are the types of Lewy body dementia (LBD)? There are two types of LBD: dementia with Lewy bodies and Parkinson's disease dementia. Both types cause the same changes in the brain. And, over time, they can cause similar symptoms. The main difference is in when the cognitive (thinking) and movement symptoms start. Dementia with Lewy bodies causes problems with thinking ability that seem similar to Alzheimer's disease. Later, it also causes other symptoms, such as movement symptoms, visual hallucinations, and certain sleep disorders. It also causes more trouble with mental activities than with memory. Parkinson's disease dementia starts as a movement disorder. It first causes the symptoms of Parkinson's disease: slowed movement, muscle stiffness, tremor, and a shuffling walk. Later on, it causes dementia. What causes Lewy body dementia (LBD)? LBD happens when Lewy bodies build up in parts of the brain that control memory, thinking, and movement. Lewy bodies are abnormal deposits of a protein called alpha-synuclein. Researchers don't know exactly why these deposits form. But they do know that other diseases, such as Parkinson's disease, also involve a build-up of that protein. Who is at risk for Lewy body dementia (LBD)? The biggest risk factor for LBD is age; most people who get it are over age 50. People who have a family history of LBD are also at higher risk. What are the symptoms of Lewy body dementia (LBD)? LBD is a progressive disease. This means that the symptoms start slowly and get worse over time. The most common symptoms include changes in cognition, movement, sleep, and behavior: Dementia, which is a loss of mental functions that is severe enough to affect your daily life and activities Changes in concentration, attention, alertness, and wakefulness. These changes usually happen from day to day. But sometimes they can also happen throughout the same day. Visual hallucinations, which means seeing things that are not there Problems with movement and posture, including slowness of movement, difficulty walking, and muscle stiffness. These are called parkinsonian motor symptoms. REM sleep behavior disorder, a condition in which a person seems to act out dreams. It may include vivid dreaming, talking in one's sleep, violent movements, or falling out of bed. This may be the earliest symptom of LBD in some people. It can appear several years before any other LBD symptoms. Changes in behavior and mood, such as depression, anxiety, and apathy (a lack of interest in normal daily activities or events) In the early stages of LBD, symptoms can be mild, and people can function fairly normally. As the disease gets worse, people with LBD need more help due to problems with thinking and movement. In the later stages of the disease, they often cannot care for themselves. How is Lewy body dementia (LBD) diagnosed? There isn't one test that can diagnose LBD. It is important to see an experienced doctor to get a diagnosis. This would usually be specialist such as a neurologist. The doctor will Do a medical history, including taking a detailed account of the symptoms. The doctor will talk to both the patient and caregivers. Do physical and neurological exams Do tests to rule out other conditions that could cause similar symptoms. These could include blood tests and brain imaging tests. Do neuropsychological tests to evaluate memory and other cognitive functions LBD can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. It's also important to know which type of LBD a person has, so the doctor can treat that type's particular symptoms. It also helps the doctor understand how the disease will affect the person over time. The doctor makes a diagnosis based on when certain symptoms start: If cognitive symptoms start within a year of movement problems, the diagnosis is dementia with Lewy bodies If cognitive problems start more than a year after the movement problems, the diagnosis is Parkinson's disease dementia What are the treatments for Lewy body dementia (LBD)? There is no cure for LBD, but treatments can help with the symptoms: Medicines may help with some of the cognitive, movement, and psychiatric symptoms Physical therapy can help with movement problems Occupational therapy may help find ways to more easily do everyday activities Speech therapy may help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling can help people with LBD and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy may reduce anxiety and improve well-being Support groups can also be helpful for people with LBD and their caregivers. Support groups can give emotional and social support. They are also a place where people can share tips about how to deal with day-to-day challenges. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 3, autosomal dominant and parkinson disease 2, autosomal recessive juvenile, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Rotigotine and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are dementia and visual hallucinations

Disease Ontology : 12 A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Genetics Home Reference : 25 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed. REM sleep behavior disorder may be the first sign of dementia with Lewy bodies. It can occur years before other symptoms appear. Individuals with REM sleep behavior disorder act out their dreams, talking and moving in their sleep when they should be still. This behavior becomes less pronounced as dementia with Lewy bodies worsens and additional features develop. Dementia is often the second major feature to develop in dementia with Lewy bodies. Initially, this intellectual decline may be mild or seem to come and go. In this condition, dementia often leads to impaired ability to perform visual-spatial tasks such as assembling puzzles. Affected individuals may also have poor problem-solving skills (executive functioning), speech difficulties, and reduced inhibitions. Problems with memory typically do not occur until later. Most people with dementia with Lewy bodies experience visual hallucinations, which often involve people or animals. Fluctuations in behavior and thought processes (cognition) include sudden changes in attention, unintelligible speech, and brief episodes of altered consciousness that may appear as staring spells. Parkinsonism is usually the last major feature to develop in people with dementia with Lewy bodies, although it can appear earlier in some individuals. The movement problems typically include tremors, rigidity, unusually slow movement (bradykinesia), and impaired balance and coordination (postural instability). Affected individuals may require walking aids or wheelchair assistance over time. Individuals with dementia with Lewy bodies may also experience a sharp drop in blood pressure upon standing (orthostatic hypotension), fainting episodes (syncope), reduced sense of smell, increased saliva production and drooling, difficulty controlling the flow of urine (incontinence), or constipation.

NIH Rare Diseases : 53 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

OMIM : 57 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

NINDS : 54 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

KEGG : 37
Lewy Body dementia (LDB) is neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. It is the second most-common degenerative dementia after Alzheimer's disease. Progressive accumulation of alpha-synuclein- and ubiquitin-positive Lewy Bodies is seen in the brainstem, the limbic system or cortical and subcortical regions, depending on disease subtype. The genetic risk factors include alpha-synuclein mutations and SNCA locus triplicationslocus triplications. Mutations of leucine-rich repeat kinase 2 (LRRK2) and the glucocerebrosidase (GBA) gene have also been implicated in familial DLB.

UniProtKB/Swiss-Prot : 74 Dementia, Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

Wikipedia : 75 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in behavior, cognition, and... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 3, autosomal dominant 33.3 SNCAIP SNCA PRKN PARK7 MAPT LRRK2
2 parkinson disease 2, autosomal recessive juvenile 32.9 SNCA PRKN PARK7 LRRK2
3 perry syndrome 32.9 TH SNCA SLC6A3 SLC18A2
4 posterior cortical atrophy 31.6 MAPT APOE
5 tremor 31.3 SNCA PRKN MAPT LRRK2 GBA
6 essential tremor 31.1 SNCA SLC6A3 PRKN LRRK2
7 dysautonomia 31.1 SNCA PRNP GBA
8 gaucher's disease 31.0 SNCA PRKN GBA
9 simultanagnosia 31.0 MAPT APOE
10 genetic prion diseases 30.9 PRNP APOE
11 cerebral amyloid angiopathy, cst3-related 30.9 PRNP MAPT APP APOE
12 dementia 30.9 SNCB SNCAIP SNCA SLC6A3 PRNP PRKN
13 pick disease of brain 30.8 SNCA RPS27A MAPT APP APOE
14 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.8 RPS27A MAPT
15 semantic dementia 30.8 RPS27A MAPT APOE
16 early-onset parkinson's disease 30.7 SNCA PRKN PARK7 LRRK2 GBA
17 creutzfeldt-jakob disease 30.7 PRNP MAPT APOE
18 postencephalitic parkinson disease 30.7 SNCA MAPT MAOB LRRK2
19 cerebrovascular disease 30.7 MAPT APP APOE ACHE
20 hereditary late-onset parkinson disease 30.7 SNCA LRRK2 GBA
21 primary lateral sclerosis, adult, 1 30.7 SNCA MAPT
22 pure autonomic failure 30.7 TH SNCA MAOB ACHE
23 prion disease 30.7 PRNP MAPT APP
24 binswanger's disease 30.7 MAPT APP APOE ACHE
25 alzheimer disease 2 30.6 MAPT BCHE APP APOE
26 corticobasal degeneration 30.6 RPS27A MAPT LRRK2 GBA
27 psychotic disorder 30.6 SLC6A3 SLC18A2 MAOB CYP2D6
28 akinetic mutism 30.5 SLC6A3 PRNP MAPT
29 leukoencephalopathy, hereditary diffuse, with spheroids 30.5 SNCA RPS27A PRNP MAPT APP
30 neuronal intranuclear inclusion disease 30.5 SNCA RPS27A MAPT
31 aphasia 30.4 SNCA PRNP MAPT APP APOE
32 neurodegeneration with brain iron accumulation 30.4 SNCG SNCB SNCA
33 rem sleep behavior disorder 30.4 SNCA SLC6A3 RPS27A LRRK2 ACHE
34 vascular dementia 30.4 MAPT BCHE APP APOE ACHE
35 parkinson disease 10 30.4 SNCA PRKN PARK7 LRRK2
36 mood disorder 30.3 TH SLC18A2 MAOB
37 multiple system atrophy 1 30.1 TH SNCB SNCA SLC6A3 RPS27A PRKN
38 frontotemporal dementia 29.8 SNCA RPS27A PRNP MAPT LRRK2 APP
39 alzheimer disease 29.7 SNCB SNCA PRNP MAPT MAOB BCHE
40 amyotrophic lateral sclerosis 1 29.7 TH SNCA RPS27A PRNP MAPT MAOB
41 movement disease 29.3 TH SNCG SNCA SLC6A3 SLC18A2 PRKN
42 supranuclear palsy, progressive, 1 29.2 TH SNCA SLC6A3 RPS27A PRKN PARK7
43 central nervous system disease 29.0 TH SNCA SLC6A3 SLC18A2 PRNP PRKN
44 nervous system disease 28.3 TH SNCA SLC6A3 PRNP PRKN PARK7
45 parkinson disease, late-onset 27.3 TH SNCG SNCB SNCAIP SNCA SLC6A3
46 parkinson disease 1, autosomal dominant 12.2
47 myoclonic epilepsy of lafora 11.4
48 parkinson disease 4, autosomal dominant 11.3
49 parkinson disease 5, autosomal dominant 11.3
50 parkinson disease 19a, juvenile-onset 11.3

Graphical network of the top 20 diseases related to Dementia, Lewy Body:



Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Human phenotypes related to Dementia, Lewy Body:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 dementia 32 HP:0000726
2 visual hallucinations 32 HP:0002367
3 parkinsonism 32 HP:0001300
4 lewy bodies 32 HP:0100315
5 delusions 32 HP:0000746
6 fluctuations in consciousness 32 HP:0007159

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
visual hallucinations
parkinsonism
delusions
fluctuations in consciousness
progressive dementia
more

Clinical features from OMIM:

127750

UMLS symptoms related to Dementia, Lewy Body:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, hallucinations, visual

MGI Mouse Phenotypes related to Dementia, Lewy Body:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ACHE APOE APP GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.36 ACHE APOE APP BCHE GBA LRRK2
3 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.27 ACHE APOE APP GBA MAPT PARK7
5 mortality/aging MP:0010768 10.21 ACHE APOE APP BCHE GBA LRRK2
6 nervous system MP:0003631 10.16 ACHE APOE APP GBA LRRK2 MAOB
7 cardiovascular system MP:0005385 10.15 APOE APP GBA LRRK2 MAPT PRKN
8 integument MP:0010771 10.1 APOE APP GBA LRRK2 MAPT PRKN
9 muscle MP:0005369 9.92 ACHE APOE APP MAPT PRKN PRNP
10 no phenotypic analysis MP:0003012 9.85 ACHE APOE APP LRRK2 MAPT PRKN
11 normal MP:0002873 9.65 APP GBA LRRK2 MAPT PRKN PRNP
12 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
2
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
5
Prazosin Approved Phase 4 19216-56-9 4893
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7
Corticosterone Experimental Phase 4 50-22-6 5753
8 Peripheral Nervous System Agents Phase 4
9 Cytochrome P-450 CYP3A Inducers Phase 4
10 Central Nervous System Stimulants Phase 4
11 Cytochrome P-450 Enzyme Inducers Phase 4
12 Wakefulness-Promoting Agents Phase 4
13 Tranquilizing Agents Phase 4
14 Central Nervous System Depressants Phase 4
15 Antipsychotic Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antidepressive Agents Phase 4
18 Quetiapine Fumarate Phase 4 111974-72-2
19 Narcotics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Analgesics Phase 4
22 Narcotic Antagonists Phase 4
23 Antipyretics Phase 4
24 Analgesics, Opioid Phase 4
25 Antihypertensive Agents Phase 4
26 Adrenergic alpha-Antagonists Phase 4
27 Adrenergic Antagonists Phase 4
28 Adrenergic alpha-1 Receptor Antagonists Phase 4
29 Adrenergic Agents Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Pharmaceutical Solutions Phase 4
32 Calamus Phase 4
33 cadexomer iodine Phase 4
34 Fluorodeoxyglucose F18 Phase 4
35
Galantamine Approved Phase 3 357-70-0 9651
36
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
37
Memantine Approved, Investigational Phase 3 19982-08-2 4054
38 Sympathomimetics Phase 3
39 Cardiotonic Agents Phase 3
40 Autonomic Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Serotonin 5-HT2 Receptor Antagonists Phase 3
43 Serotonin Agents Phase 3
44 Antiparkinson Agents Phase 3
45 Excitatory Amino Acid Antagonists Phase 3
46 Excitatory Amino Acids Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Carvedilol Approved, Investigational Phase 2 72956-09-3 2585
49
Ambroxol Approved, Investigational Phase 2 18683-91-5
50
Donepezil Approved Phase 2 120014-06-4 3152

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
2 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
3 A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
4 An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies Completed NCT01023672 Phase 4 Armodafinil
5 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
6 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
7 Prazosin and CSF Biomarkers in mTBI Recruiting NCT03221751 Phase 4 prazosin hydrochloride;placebo
8 Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation NCT03582488 Phase 4 18F-Flortaucipir
9 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
10 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
11 Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type Unknown status NCT00190021 Phase 3 donepezil
12 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
13 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
14 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
15 Oculomotor Recording in the Contribution to the Early Differential Diagnosis of Dementia With Lewy Bodies and Alzheimer's Disease Completed NCT01577394 Phase 3
16 An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
17 An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis Completed NCT01550484 Phase 2, Phase 3 18F-AV-133
18 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
19 Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine Not yet recruiting NCT03858270 Phase 3 Memantine
20 A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
21 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
22 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
23 Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
24 A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
25 A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH) Completed NCT02640729 Phase 2 Nelotanserin;Placebo
26 Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
27 A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00630500 Phase 2 Memantine;Placebo
28 A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD) Completed NCT02708186 Phase 2 Nelotanserin;Placebo
29 A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies Recruiting NCT03467152 Phase 2 E2027;Placebo
30 Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Recruiting NCT03305809 Phase 2 LY3154207;Placebo
31 A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB) Recruiting NCT04001517 Phase 2 Neflamapimod
32 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Recruiting NCT03888222 Phase 2 Placebo Oral Tablet;Bosutinib Oral Tablet
33 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies (DLB) Recruiting NCT04002674 Phase 2 Placebo oral capsule;Nilotinib Oral Capsule
34 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of K0706 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Recruiting NCT03996460 Phase 2 Placebo oral capsule;96 mg of K0706;192 mg K0706
35 Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes Recruiting NCT03555292 Phase 2 11C-PiB
36 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
37 Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia Recruiting NCT02914366 Phase 2 Ambroxol
38 Imaging Inflammation in Patients With Diffuse Lewy Body Disease Active, not recruiting NCT02702102 Phase 2 11C-PBR28
39 A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease Active, not recruiting NCT03189563 Phase 2 DA-9805 45mg;DA-9805 90mg
40 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease Active, not recruiting NCT02947893 Phase 2 Placebo Capsule(s) Once a Day by Mouth;Nilotinib Capsule(s) Once a Day by Mouth
41 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Active, not recruiting NCT02450786 Phase 2 Donepezil
42 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Active, not recruiting NCT02954978 Phase 2 Placebo Oral Capsule;Nilotinib 150mg oral capsule [Tasigna];Nilotinib 300mg oral capsule [Tasigna]
43 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment Not yet recruiting NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
44 A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies Suspended NCT03592862 Phase 2 HTL0018318;Placebo
45 An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder Terminated NCT02871427 Phase 2 Nelotanserin
46 An Open-Label Trial of Donepezil in Fragile X Syndrome Completed NCT00220584 Phase 1 donepezil
47 Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein Completed NCT02281474 Phase 1 Nilotinib
48 An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease Recruiting NCT03764215 Phase 1 Nilotinib 150 MG
49 An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation With Fetal Ventral Mesencephalic Tissue in Patients With Parkinson's Disease Active, not recruiting NCT01898390 Phase 1
50 An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects Not yet recruiting NCT04023877 Phase 1 E2027

Search NIH Clinical Center for Dementia, Lewy Body

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Donepezil
Galantamine
Rivastigmine

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 29 GBA SNCA SNCB
2 Lewy Bodies 29

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

41
Brain, Testes, Heart, Eye, Skin, Colon, Cortex

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 917)
# Title Authors PMID Year
1
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. 9 38 8 71
14755719 2004
2
Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. 8 71
18852445 2008
3
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. 8 71
18332251 2008
4
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. 8 71
18195271 2008
5
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. 8 71
16358335 2006
6
Beta-synuclein gene alterations in dementia with Lewy bodies. 8 71
15365127 2004
7
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. 9 8
18335262 2008
8
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. 9 8
18413475 2008
9
A novel PSEN2 mutation associated with a peculiar phenotype. 38 8
18427071 2008
10
An Overview of Primary Dementias as Clinicopathological Entities. 38 17
30925609 2019
11
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. 8
29743672 2018
12
The L444P GBA mutation is associated with early-onset Parkinson's disease in Mexican Mestizos. 71
23448517 2013
13
A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. 71
22713811 2013
14
Gaucher disease: frequency of the N370S mutation in the Greek population. 71
20662857 2010
15
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. 71
19286695 2009
16
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 71
18852448 2008
17
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 71
18852449 2008
18
The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. 71
18541817 2008
19
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. 71
17625105 2008
20
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. 71
18022370 2007
21
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. 71
17620502 2007
22
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. 71
17251522 2007
23
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. 8
16790605 2006
24
Lrrk2 and Lewy body disease. 8
16437559 2006
25
Biochemical and pathological characterization of Lrrk2. 8
16437584 2006
26
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. 8
16237129 2005
27
A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. 8
15732120 2005
28
The E46K mutation in alpha-synuclein increases amyloid fibril formation. 71
15632170 2005
29
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. 71
15498564 2004
30
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. 71
15451224 2004
31
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. 71
15451225 2004
32
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. 71
14755720 2004
33
alpha-Synuclein locus triplication causes Parkinson's disease. 71
14593171 2003
34
Dementia with Lewy bodies: disease concept and genetics. 8
12898286 2003
35
A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. 8
12451207 2002
36
Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology. 8
11890854 2002
37
[Diagnostic criteria of diffuse Lewy body disease]. 8
11068444 2000
38
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. 71
10796875 2000
39
Familial dementia with Lewy bodies (DLB). 8
10505432 1999
40
Autosomal dominant diffuse Lewy body disease. 8
9705138 1998
41
Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 71
9554746 1998
42
Familial parkinsonism, dementia, and Lewy body disease: study of family G. 8
9382476 1997
43
Clinical features of familial diffuse Lewy body disease. 8
9276199 1997
44
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. 8
8909416 1996
45
Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 71
7789963 1995
46
The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. 8
7818242 1995
47
The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. 8
7936253 1994
48
Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. 71
8516282 1993
49
Gaucher's disease in the United Kingdom: screening non-Jewish patients for the two common mutations. 71
8487270 1993
50
Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. 71
8450045 1993

Variations for Dementia, Lewy Body

ClinVar genetic disease variations for Dementia, Lewy Body:

6 (show all 17)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 GBA NM_001005741.3(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic rs80356771 1:155204987-155204987 1:155235196-155235196
2 GBA NM_001005741.3(GBA): c.1604G> A (p.Arg535His) single nucleotide variant Pathogenic rs75822236 1:155204793-155204793 1:155235002-155235002
3 GBA NM_001005741.3(GBA): c.887G> A (p.Arg296Gln) single nucleotide variant Pathogenic rs78973108 1:155207244-155207244 1:155237453-155237453
4 SNCB NM_001001502.3(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 5:176053473-176053473 5:176626472-176626472
5 SNCB NM_001001502.3(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 5:176048219-176048219 5:176621218-176621218
6 SNCA NM_000345.4(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 4:90749300-90749300 4:89828149-89828149
7 SNCA NM_000345.4(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 4:90749321-90749321 4:89828170-89828170
8 SNCA SNCA, DUPLICATION duplication Pathogenic
9 GBA NM_001005741.3(GBA): c.115+1G> A single nucleotide variant Pathogenic rs104886460 1:155210420-155210420 1:155240629-155240629
10 SNCA NC_000004.11: g.(?_90647315)_(90756838_?)dup duplication Pathogenic 4:90647315-90756838 4:89726164-89835687
11 SNCA NC_000004.11: g.(?_90647315)_(90756828_?)dup duplication Pathogenic 4:90647315-90756828 4:89726164-89835677
12 GBA NM_001005741.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 1:155205043-155205043 1:155235252-155235252
13 GBA NM_001005741.3(GBA): c.1297G> T (p.Val433Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80356769 1:155205563-155205563 1:155235772-155235772
14 GBA NM_001005741.3(GBA): c.1342G> C (p.Asp448His) single nucleotide variant Pathogenic/Likely pathogenic rs1064651 1:155205518-155205518 1:155235727-155235727
15 GBA NM_001005741.3(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs76763715 1:155205634-155205634 1:155235843-155235843
16 SNCA NM_000345.4(SNCA): c.349C> A (p.Pro117Thr) single nucleotide variant Uncertain significance 4:90650386-90650386 4:89729235-89729235
17 SNCA NM_000345.4(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 4:90647794-90647794 4:89726643-89726643

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

74
# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 TH SNCAIP SNCA SLC6A3 SLC18A2 RPS27A
2
Show member pathways
13.25 TH SNCAIP SNCA SLC6A3 SLC18A2 PRKN
3
Show member pathways
12.53 SNCAIP SNCA SLC6A3 PRKN PARK7
4 11.9 TH SNCB SNCA RPS27A PRNP PRKN
5
Show member pathways
11.8 TH SLC6A3 SLC18A2 MAOB
6 11.77 SLC18A2 MAOB CYP2D6 APP
7 11.62 TH SNCAIP SNCA SLC6A3 PRKN PARK7
8 11.42 PRNP MAPT APP
9 11.32 MAPT APP APOE
10
Show member pathways
11.29 TH SLC6A3 ACHE
11 11.2 CYP2D6 APOE ACHE
12 11.02 TH SLC6A3 SLC18A2
13 10.94 TH SNCA SLC6A3 PRKN PARK7 MAOB
14
Show member pathways
10.91 SLC6A3 BCHE ACHE
15 10.7 TH MAOB
16 10.63 TH ACHE
17 10.62 RPS27A PRKN

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.99 SNCG SNCA PRKN PARK7 APP ACHE
2 dendrite GO:0030425 9.96 TH PRNP MAPT LRRK2 APOE
3 neuron projection GO:0043005 9.87 TH SLC6A3 PRKN PARK7 MAPT LRRK2
4 mitochondrial outer membrane GO:0005741 9.83 SNCA RPS27A MAOB LRRK2
5 postsynapse GO:0098794 9.8 SNCA PRNP LRRK2
6 synaptic vesicle GO:0008021 9.77 TH SNCAIP SNCA SLC18A2 LRRK2
7 growth cone GO:0030426 9.76 SNCA MAPT LRRK2 APP
8 synaptic vesicle membrane GO:0030672 9.74 SNCA SLC18A2 LRRK2
9 presynapse GO:0098793 9.73 SNCB SNCA PRKN PARK7
10 membrane raft GO:0045121 9.73 SLC6A3 PRNP PARK7 MAPT LRRK2 APP
11 terminal bouton GO:0043195 9.71 TH SNCA SLC18A2 LRRK2
12 synaptic cleft GO:0043083 9.6 APOE ACHE
13 dopaminergic synapse GO:0098691 9.59 SLC6A3 SLC18A2
14 neuronal cell body GO:0043025 9.56 TH SNCG SNCAIP SNCA SLC6A3 MAPT
15 nuclear envelope lumen GO:0005641 9.55 BCHE APP
16 main axon GO:0044304 9.54 MAPT APP
17 inclusion body GO:0016234 9.46 SNCB SNCA PRNP LRRK2
18 axon GO:0030424 9.23 TH SNCG SNCA SLC6A3 PARK7 MAPT
19 membrane GO:0016020 10.48 SNCA SLC6A3 SLC18A2 RPS27A PRNP PARK7
20 cytoplasm GO:0005737 10.35 TH SNCG SNCB SNCAIP SNCA SLC6A3
21 extracellular space GO:0005615 10.19 SNCA RPS27A LRRK2 GBA BCHE APP
22 endoplasmic reticulum GO:0005783 10.16 PRNP PRKN PARK7 LRRK2 CYP2D6 BCHE
23 Golgi apparatus GO:0005794 10.12 SNCA PRNP PRKN LRRK2 APP APOE
24 mitochondrion GO:0005739 10.1 TH SNCA PRKN PARK7 MAPT MAOB
25 synapse GO:0045202 10.01 SNCB SNCA LRRK2 APP ACHE

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.97 SNCAIP SNCA RPS27A PRKN APP APOE
2 negative regulation of neuron apoptotic process GO:0043524 9.95 SNCB SNCA PRKN PARK7 APOE
3 response to ethanol GO:0045471 9.92 TH SLC6A3 MAOB
4 response to oxidative stress GO:0006979 9.91 PRNP PRKN LRRK2 APP APOE
5 cellular response to oxidative stress GO:0034599 9.9 SNCA PARK7 LRRK2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 SNCA PARK7 APP
7 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.88 PRKN LRRK2 GBA
8 mitochondrion organization GO:0007005 9.88 PRKN PARK7 LRRK2 GBA
9 locomotory behavior GO:0007626 9.88 TH SLC6A3 SLC18A2 PRKN APP
10 positive regulation of protein binding GO:0032092 9.86 PRKN LRRK2 APP
11 regulation of autophagy GO:0010506 9.86 PRKN MAPT LRRK2
12 learning GO:0007612 9.86 TH PRKN BCHE APP
13 negative regulation of protein phosphorylation GO:0001933 9.83 SNCA PRNP PRKN PARK7 LRRK2
14 protein destabilization GO:0031648 9.82 SNCA PRNP PRKN
15 positive regulation of neuron death GO:1901216 9.8 SNCA PRNP MAPT
16 regulation of dopamine secretion GO:0014059 9.78 SNCG SNCA PRKN
17 cellular response to copper ion GO:0071280 9.77 SNCA PRNP APP
18 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.75 PRKN PARK7 LRRK2
19 response to metal ion GO:0010038 9.74 TH SNCB
20 microglial cell activation GO:0001774 9.74 SNCA MAPT
21 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.74 PRNP APP
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 PARK7 LRRK2
23 negative regulation of protein processing GO:0010955 9.74 PRNP LRRK2
24 neurotransmitter biosynthetic process GO:0042136 9.74 TH SLC6A3 ACHE
25 locomotory exploration behavior GO:0035641 9.73 LRRK2 APOE
26 cellular response to dopamine GO:1903351 9.73 PRKN LRRK2
27 cellular copper ion homeostasis GO:0006878 9.73 PRNP APP
28 supramolecular fiber organization GO:0097435 9.73 SNCA MAPT
29 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.73 SLC18A2 PARK7
30 regulation of protein metabolic process GO:0051246 9.72 GBA APOE
31 virion assembly GO:0019068 9.72 RPS27A APOE
32 amyloid precursor protein metabolic process GO:0042982 9.72 APOE ACHE
33 adult locomotory behavior GO:0008344 9.72 SNCG SNCA PRKN PARK7 APP
34 regulation of dopamine metabolic process GO:0042053 9.71 SLC6A3 PRKN
35 positive regulation of protein metabolic process GO:0051247 9.71 GBA APP
36 neurotransmitter catabolic process GO:0042135 9.71 MAOB ACHE
37 neuron projection maintenance GO:1990535 9.71 PRNP APP
38 negative regulation of amyloid-beta formation GO:1902430 9.71 PRNP APOE
39 negative regulation of long-term synaptic potentiation GO:1900272 9.71 PRNP APP APOE
40 regulation of neurotransmitter secretion GO:0046928 9.71 SNCG SNCAIP SNCA PRKN
41 astrocyte activation GO:0048143 9.7 MAPT APP
42 regulation of locomotion GO:0040012 9.7 SNCA LRRK2
43 positive regulation of microglial cell activation GO:1903980 9.7 LRRK2 APP
44 dopamine biosynthetic process GO:0042416 9.7 TH SNCA SLC6A3
45 monoamine transport GO:0015844 9.69 SLC6A3 SLC18A2
46 intracellular distribution of mitochondria GO:0048312 9.69 MAPT LRRK2
47 amyloid fibril formation GO:1990000 9.69 MAPT APP
48 regulation of mitochondrial fission GO:0090140 9.68 MAPT LRRK2
49 mating behavior GO:0007617 9.68 TH APP
50 dopamine catabolic process GO:0042420 9.67 SLC6A3 MAOB

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.81 SNCA PRNP MAPT LRRK2
2 chaperone binding GO:0051087 9.74 PRNP PRKN MAPT
3 enzyme binding GO:0019899 9.7 TH SNCA PRKN PARK7 MAPT BCHE
4 copper ion binding GO:0005507 9.65 SNCA PRNP PARK7
5 identical protein binding GO:0042802 9.65 SNCAIP SNCA PRNP PRKN PARK7 MAPT
6 amyloid-beta binding GO:0001540 9.62 PRNP BCHE APOE ACHE
7 tau protein binding GO:0048156 9.58 SNCA APOE
8 ubiquitin-specific protease binding GO:1990381 9.56 PRKN PARK7
9 tubulin binding GO:0015631 9.56 PRNP PRKN MAPT LRRK2
10 phospholipase binding GO:0043274 9.55 SNCA PRKN
11 dopamine binding GO:0035240 9.54 TH SLC6A3
12 monoamine transmembrane transporter activity GO:0008504 9.49 SLC6A3 SLC18A2
13 lipoprotein particle binding GO:0071813 9.46 MAPT APOE
14 cupric ion binding GO:1903135 9.43 PRNP PARK7
15 cholinesterase activity GO:0004104 9.4 BCHE ACHE
16 acetylcholinesterase activity GO:0003990 9.37 BCHE ACHE
17 cuprous ion binding GO:1903136 8.92 SNCB SNCA PRNP PARK7
18 protein homodimerization activity GO:0042803 10 PARK7 MAPT MAOB LRRK2 APOE ACHE

Sources for Dementia, Lewy Body

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....